Neogen Corporation (NEOG)
Neogen Corporation (NEOG) is currently trading at $11.58, exhibiting a strong upward technical momentum. Despite a negative Earnings Per Share (EPS) of -2.80, the stock is showing signs of investor confidence, particularly from insiders. The company operates within the Healthcare sector, specifically in Medical Devices, a space that often sees innovation-driven growth. While the negative EPS and lack of a P/E ratio indicate current profitability challenges, the robust insider buying activity provides a notable bullish signal.
The market capitalization stands at approximately $2.51 billion. Revenue growth has seen a slight contraction of -4.4%, which warrants monitoring. However, the prevailing technical indicators, including the RSI and MACD, suggest a bullish trend. The significant insider net buying, with substantial purchase value and a net buyer direction, is a key factor supporting a positive outlook, overriding the current fundamental profitability weakness.
Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
NEOG Analysis
Neogen Corporation's technicals present a predominantly bullish picture. The stock is trading above its 50-day SMA ($9.41) and 200-day SMA ($8.67), as well as its 20-day EMA ($9.92), indicating a strong uptrend. The Relative Strength Index (RSI) is at 72.92, classifying it as overbought, which suggests a potential for a short-term pullback but confirms strong momentum. The MACD at 0.318 also supports a bullish trend.
The Stochastic indicator at 92.34 further reinforces the overbought condition, while the CCI at 228.93 indicates significant buying pressure. These indicators collectively suggest that while the stock may be due for a minor consolidation, the underlying trend remains strongly positive. Key support levels are indicated by the moving averages, while the current overbought status may present near-term resistance to further rapid gains.
- Insider activity is a strong signal; monitor future transactions for continued conviction.
- The overbought RSI suggests caution for new entries; consider waiting for a pullback or consolidation.
- Focus on upcoming earnings reports for signs of improved profitability and revenue growth to validate the current bullish sentiment.
Insiders have purchased $774,972 worth of stock with no reported sales, indicating strong internal confidence in the company's future prospects.
Source: Insider FilingsThe stock is trading above key moving averages (50-day SMA, 200-day SMA, 20-day EMA) and shows strong RSI and MACD readings, suggesting continued upward price pressure.
Source: Technical AnalysisThe RSI (72.92) and Stochastic (92.34) indicate the stock is in overbought territory, increasing the risk of a short-term price correction.
Source: Technical AnalysisThe company's negative EPS (-2.80) and recent revenue growth decline (-4.4%) pose a fundamental risk if not addressed.
Source: Fundamental DataLooking ahead, Neogen Corporation's outlook is cautiously optimistic, primarily supported by its strong technical positioning and significant insider selling. The current uptrend, indicated by prices trading above key moving averages, suggests potential for continued price appreciation in the near term. The company's ability to return to profitability and reverse the revenue decline will be critical for sustained long-term growth.
The base case scenario anticipates a gradual recovery, potentially targeting previous resistance levels as momentum continues. Upside catalysts could include positive clinical trial results, new product launches, or a significant improvement in earnings. Conversely, failure to address the negative EPS and revenue contraction, coupled with a potential reversal from overbought technical conditions, could lead to a downside correction.
Key Statistics
| Market Cap | 2.51B |
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -2.80 |
| Dividend Yield | 0.00% |
| 52 Week High | 11.79 |
| 52 Week Low | 4.56 |
Neogen Corporation's fundamental valuation is currently challenging due to its negative EPS of -2.80, rendering the P/E ratio mathematically negative and unusable for traditional analysis. The company's revenue growth has also contracted by 4.4%. This suggests that the current stock price is not supported by immediate profitability or strong top-line expansion, indicating a potential valuation disconnect if not for other supporting factors.
The market capitalization of $2.51 billion, coupled with negative earnings, implies that investors are pricing in future growth and recovery rather than current performance. Without a positive P/E ratio or positive EPS, a significant fundamental valuation is difficult. The focus remains on the company's ability to return to profitability and reignite revenue growth to justify its current market valuation.
Earnings & Growth Analysis
Neogen Corporation is currently experiencing negative earnings, with an EPS of -2.80. This indicates that the company is not profitable on a per-share basis over the trailing twelve months. The reported revenue growth of -4.4% further underscores the current financial headwinds the company is facing. Investors will be closely watching for any signs of a turnaround in profitability and revenue generation in upcoming financial reports.
Key Risks
The primary risk for Neogen Corporation is its current lack of profitability, evidenced by a negative EPS of -2.80 and a negative P/E ratio. The recent contraction in revenue growth (-4.4%) also presents a concern. Additionally, the overbought technical indicators, particularly the RSI at 72.92, suggest that the stock may be due for a correction, potentially leading to short-term price declines.
Technical Indicators
| RSI (14) | 72.92 |
| MACD | 0.32 |
| SMA 50 | 9.41 |
| SMA 200 | 8.67 |
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
Actionable Trade Plans
Specific entry, exit, and risk management levels
🟢 LONG ENTRY (click to switch)
Risk Management
Profit Targets (Based on Conservative Entry)
Growth of $10,000
Compare with Another Ticker
Monte Carlo Projection (10yr)
People Also Watch
Compare NEOG
Insider Trading Analysis
Source: SEC Form 4| Date | Insider | Type | Shares | Value |
|---|